A new scientific event in Gothenburg

Life Science Sweden is holding an event in Gothenburg for the first time.

Nocebo – the evil twin that makes you feel worse

The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...

ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.

Quretech granted a European patent for a new type of antibiotic

The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.

Gothenburg-based company acquired by Norwegian diagnostics group

Gentian Diagnostics acquires Gothenburg-based Getica.

Samuel Lagercrantz: ”Will the Swedish life science strategy be updated with precision?”

What will the Swedish government focus on in the life science strategy that is being updated? And what should be prioritized in the strategy? Life Science Swede...

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job...

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

Event: Drug Development – Serendipity or Science

Drug development is a challenging journey, we will discuss questions you may not even consider asking. SDS and Medicon Village welcome you to an engaging afternoon.

Affibody AB

Lonza

Rise and Scantox cease conducting animal testing in Stockholm

Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...

Första godkännandet för behandling byggd på gensaxen Crispr

För första gången har en behandling som bygger på den Nobelprisvinnande genredigeringstekniken Crispr fått ett marknadsgodkännande. Det är brittiska myndigheter...

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

The Top 10 Challenges Facing Laboratories Today

Navigating the Laboratory Automation Landscape

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)

Han är Abilias nya produktchef

Hjälpmedelsföretaget Abilia anställer Johan Tegstam som Chief Product Officer.

Lundabolag beviljas särläkemedelsstatus i USA

Bioteknikbolaget Cantargias läkemedel CAN10 för behandling av systemisk skleros har nu beviljats status som särläkemedel i USA.

Investigations against AstraZeneca: ”Chinese interests may be behind them”

Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.